TRAX · XBRL financial data
First Tracks Biotherapeutics financial statements, every quarter
The same tables from 3 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal quarters
| In thousands of dollars | Mar 31, 2026 | Jun 30, 2026 | Sep 30, 2026 |
|---|---|---|---|
| Research and development | 33,955 | 25,644 | 23,846 |
| General and administrative | 18,856 | 9,293 | 8,998 |
| Total operating expenses | 52,811 | 34,937 | 32,844 |
| Operating income (loss) | (52,811) | (34,937) | (32,844) |
| Other income (expense) | (1) | (1) | (7) |
| Net income (loss) | (50,484) | (33,374) | (31,356) |
| Earnings per share, basic USD per share | — | (0.95) | (0.88) |
| Earnings per share, diluted USD per share | — | (0.95) | (0.88) |
| Weighted average shares, basic thousands of shares | — | 35,003 | 35,747 |
| Weighted average shares, diluted thousands of shares | — | 35,003 | 35,747 |
Balance sheet
CSVFiscal quarters
| In thousands of dollars | Mar 31, 2026 | Jun 30, 2026 | Sep 30, 2026 |
|---|---|---|---|
| Cash and cash equivalents | 248,469 | 168,018 | 155,627 |
| Marketable securities | 37,986 | 0 | 0 |
| Prepaid and other current assets | 2,947 | 9,727 | 10,095 |
| Total current assets | 289,402 | 177,745 | 165,722 |
| Property and equipment, net | 1,174 | 1,071 | 979 |
| Right-of-use asset | 0 | 4,324 | 3,755 |
| Total assets | 290,576 | 183,140 | 170,456 |
| Accounts payable | 7,496 | 2,553 | 3,949 |
| Accrued liabilities | 25,616 | 7,458 | 11,723 |
| Total current liabilities | 33,112 | 12,447 | 18,090 |
| Lease liability, non-current | 0 | 1,897 | 1,355 |
| Accumulated deficit | — | (24,576) | (55,932) |
| Total stockholders' equity | 257,464 | 168,796 | 151,011 |
| Total liabilities and equity | 290,576 | 183,140 | 170,456 |
| Common shares outstanding (cover page) thousands of shares | 34,892 | 35,731 | 42,018 |
Cash flows
CSVFiscal quarters
| In thousands of dollars | Mar 31, 2026 | Jun 30, 2026 | Sep 30, 2026 |
|---|---|---|---|
| Net income (loss) | (50,484) | (33,374) | (31,356) |
| Stock-based compensation | 11,503 | 8,319* | 8,897* |
| Depreciation and amortization | 125 | 105* | 92* |
| Net cash from operating activities | (32,561) | (31,918)* | (17,051)* |
| Purchases of property and equipment | 17 | 25* | 0* |
| Net cash from investing activities | 34,983 | (25)* | 0* |
| Proceeds from issuing common stock | — | — | 0* |
| Net cash from financing activities | 7,851 | (48,508)* | 4,660* |
| Net change in cash | 10,273 | (80,451)* | (12,391)* |
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
- A cell reading “year only” links to a 10-K that gives only the full year: without all three earlier quarters there is no fourth quarter to work out, and the year total is never shown as a quarter.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| First Tracks Biotherapeutics | 155,627 | not reported | (17,051)* | 42.0M | 5.7 quarters | 10-QSep 30, 2026 |
| America Great Health | 29 | 26 | 1.7* | 21.2B | — | 10-QMar 31, 2026 |
| AbbVie | 10,774,000 | 17,404,000 | 7,606,000* | 1.8B | — | 10-QSep 30, 2026 |
| Abeona Therapeutics | 56,229 | 11,380 | (17,496)* | 57.2M | 8.4 quarters | 10-QJun 30, 2026 |
| Abbott Laboratories | 4,052,000 | 13,013,000 | 1,737,000* | 1.7B | — | 10-QSep 30, 2026 |
| Arbutus Biopharma | 19,171 | 1,014 | (6,018)* | 197.8M | 15.4 quarters | 10-QJun 30, 2026 |
| Abvc Biopharma | 32 | not reported | (244)* | 26.7M | 0.4 quarters | 10-QJun 30, 2026 |
| Acadia Pharmaceuticals | 322,365 | 342,291 | 11,503* | 172.8M | — | 10-QSep 30, 2026 |
| AC Immune | 26,795 | year only | year only | 101.7M | — | 20-FDec 31, 2025 |
Not investment advice. Not affiliated with the U.S. SEC.
Data on this page was fetched . The filing on SEC.gov is the record.